CHU de Bordeaux
Bordeaux, France
NCT Number: NCT04272281
the aim of this trial is to demonstrate that when caring women with symptoms of acute cystitis without any risk of complication, general practitioner may use share decision making tool to help patients better understand the stakes of taking antibiotics.
Looking for future studies?
Notify Me18 year–65 year
Female
Interventional
Not applicable
Bordeaux, France
Each year, more than 2.000.000 patients visit their general practitioners for a acute cystitis. The scientific literature shows that acute cystitis without risk of complication cause complications, such as pyelonephritis, in a very rare cases. However, French guidelines systematically request an antibiotic therapy as soon as the diagnostic is confirmed with the only goal to lowering symptomatology.
Recent studies show that some informed women would like not to take antibiotics and pain-killers could be as effective as antibiotics. Canadian studies assessing share decision making tools in patients with acute respiratory infection have shown that matching antibiotic treatment with the patient values lower such prescription without any impact on clinical outcomes .
Investigators aim to assess a similar strategy in patients with acute cystitis. This study will compare a group following French guidelines versus one using a share decision making tool to determine if, after being informed of the benefice and risk of this treatment, patient still want an antibiotic. Targeting instead of systematic prescription will reduce antibiotic consumption.
After diagnostic of acute cystitis to a woman between 18 and 65 years, investigators check if they filing all study criteria and ask for authorization to add them to the study. Then they'll act following their group instruction, and get information (antibiotic prescription or not, score to the Activity Impairment Assessment (AIA) scale, Score to satisfaction scale). Then patients will be followed by phone contact on day 5, day 14 and day 90 after inclusion to get information on antibiotic use, AIA and satisfaction scores and clinical outcomes, such urinary infection. Data on antibiotics delivery by pharmacy will be obtained through National assurance database.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The experimental group will use the share decision making tool during consultation to adapt antibiotherapy
control group will act as usual in their practice.
Time frame: Day 14 after inclusion (day 0)
Time frame: Day 0, Day 5 and Day14
Scale from 0 (never) to 4 (always) on several items about usuals activities limitations.
Time frame: Day 0, Day 5, Day14 and Day 90
Scale from 0 (not satisfied) to 10 (very satisfied) on satisfation about medical care.
Time frame: Between Day 15 and Day 90
Infection reccurence will be assessed with the number of dispensation of antibiotics between day 15 and day 90.
University Hospital, Bordeaux
Other
Utilisation d'un Outil de décision médicale partagée Dans la Prise en Charge Des Cystites Aigues Sans Risque de Complication en médecine générale : Comparaison de la Consommation d'Antibiotique Entre Deux Groupes randomisés en Cluster.
Acronym: ARIBO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05584657
Cystitis, Female Urogenital Diseases
Cullman, Alabama, United States
View Trial DetailsNCT05945667
Cystitis, Female Urogenital Diseases
Moscow, Russia
View Trial DetailsNCT04987164
Cystitis, Female Urogenital Diseases
Dijon, Bourgogne-Franche-Comté, France
View Trial DetailsNCT03877289
Cystitis, Female Urogenital Diseases
Calgary, Alberta, Canada
View Trial Details